PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Defibrillators, Implantable”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 883 records · Page 49Linked to original sources
PubMed1997

Management of infected implantable cardiac defibrillators.

BACKGROUND: The implantable cardiac defibrillator (ICD) was introduced clinically in 1980 for the management of ventricular arrhythmias. METHODS: From January 31, 1989, through May 29, 1996, 329 ICD devices were implanted at Allegheny University Hospital, Hahnemann Division, Philadelphia, Pennsylvania. All device-related infections were examined. RESULTS: Fifteen patients (5%) experienced infection of the generator component of the ICD. There were 14 male and 1 female patients with a mean age of 62 years (range, 38 to 79 years). All infections involved the generator with or without other component involvement. Complete removal of the system was performed in 7 patients, partial removal in 5, and the entire system was left intact in 3. In 4 patients (27%), further procedures were performed to remove additional infection. Three patients (20%) died during the hospital stay. CONCLUSIONS: Infection of ICD devices is a devastating event. We favor complete removal of the ICD generator and all the components when possible. Partial removal of the ICD unit (ie, generator only) is reserved for patients in whom the risk of complete removal is too high and infection is confined to the generator only.

Adult↗
PubMedDate not supplied

Description of a nursing intervention program after an implantable cardioverter defibrillator.

BACKGROUND: Although implantable cardioverter defibrillator (ICD) therapy has been found to be effective in preventing and treating life-threatening arrhythmias, adjusting to the ICD and resuming a normal lifestyle are often difficult. There are few intervention trials reported in the literature to aid in adjustment after receiving a primary ICD. OBJECTIVE: This article describes the content and structure of a nursing intervention program designed to improve physical functioning and psychologic adjustment after ICD implantation. The nursing intervention program was based on social cognitive theory and the data from a previous investigation covering 7 areas of concern after ICD implantation. CONCLUSION: Hospital-based education programs begin the process of recovery after ICD implantation, but they must be supplemented with further interventions to return the patient to baseline physical and psychologic functioning. This is a beginning effort in deriving and testing evidence-based intervention programs for patients with an ICD.

Adaptation, Psychological↗
PubMed1998

[Current indications for implantable automatic defibrillators].

Since the first implantation in man in 1980 implantable cardioverter defibrillator technology has greatly improved and the number of devices implanted has increased considerably in recent years. Non-thoracotomy lead systems and biphasic shocks are now the approach of choice, offering nearly a 100% success rate. This paper version reviews the current indications for the implantation of implantable cardioverter defibrillator and is an upgraded of an article previously published by the Arrhythmia's Section of the Spanish Society of Cardiology. Recommendations for qualification of centres implanting defibrillators and follow up are also addressed.

Aged↗
PubMed1994

The implantable cardioverter defibrillator: the end of the thoracotomy approach.

Internal cardioverter defibrillator (ICD) implantation has become a standard therapy for life-threatening arrhythmias. A simple and safe surgical implantation technique is therefore mandatory in this high risk population. In a 30-month period 86 patients received 87 ICD devices. An endocavitary lead system was used as first choice in 62 patients and defibrillation thresholds (DFT) of 25 joules (J) or less were obtained in 57 patients. A thoracotomy approach was avoided using a biphasic shock wave form in 17 patients and the addition of a subcutaneous (sc) patch in 11 patients or wire array lead in 9 patients. There was one early non-technique related death (1.7%) after the transvenous approach. Reoperation was necessary in three patients with lead complications and in two patients for local device problems (one migration, one infection). With the recent progress in ICD technology, a thoracotomy approach could be avoided for the last 52 patients. For comfort and cosmetic reasons left subcostal insertion of the device has been successfully used in the last 50 patients. We conclude that the nonthoracotomy approach can now be offered to all patients in need for an ICD as a consequence of the technological progress made in the field of electric treatment of malignant ventricular arrhythmias. A stepwise approach with a minimum of implanted hardware and the use of biphasic shock systems now offers a simple and efficient treatment alternative with very low perioperative risk. Internal cardioverter defibrillator implantation in combination with open heart procedures can easily be avoided.

Adolescent↗
PubMed1993

Total pectoral implantation: a new technique for implantation of transvenous defibrillator lead systems and implantable cardioverter defibrillator.

We describe a new approach to total pectoral implantation of cardioverter defibrillators with an endocardial defibrillation lead system. Endocardial lead configuration used was an FDA approved right atrial-superior vena cava defibrillation spring electrode, right ventricular bipolar sensing electrode, and a pectoral patch. Endocardial leads were implanted via a cephalic or an axillary venesection. Pectoral patch was placed in a submuscular position. In case of failure to obtain satisfactory thresholds, a small intercostal thoracotomy was performed via the same skin incision and patch placed over the epicardium instead of submuscular position and used with the right atrial spring electrode. The device was implanted in the pectoral region, submuscularly, over the patch. Sixteen consecutive patients underwent this approach. With a submuscular patch, adequate defibrillation thresholds (< or = 15 joules [J]) were obtained in 14 (87.5%) patients. In the other two, defibrillation thresholds of < or = 15 J were obtained with a epicardial patch. Pectoral implantation of the device was feasible in all 16 patients and none needed repositioning. Average postimplant hospital stay was 5 days. During follow-up period (average 5 months), none of the patients reported any major local symptoms and no problems have been encountered in device interrogation. Thus, total pectoral implantation of the cardioverter defibrillator including the patch, leads, and the device is feasible. Furthermore, in case of failure to obtain adequate defibrillation thresholds with submuscular patch, an epicardial patch can easily be implanted and allows 100% successful defibrillation at energy levels of < or = 15 J with right atrial patch configuration.

Adult↗
PubMed1992

The automatic implantable cardioverter-defibrillator. Long-term clinical experience and outcome at a hospital without an open-heart surgery program.

From November 1982 through April 1989, 111 patients with refractory sustained ventricular tachycardia/fibrillation had the automatic cardioverter-defibrillator implanted at our institution, the first community hospital involved in implantation of such a device. We have reviewed our long-term clinical experience to assess the feasibility, learning curve, and efficacy of device implantation in a facility with cardiac electrophysiology expertise but without open-heart surgery facilities. All patients were considered inoperable or at high risk for other concomitant surgery. Eighty-six patients (77%) underwent uneventful implantation. Nine patients (8%) died prior to hospital discharge. Operative mortality declined from 10.9% to 5.4% during the first half (55 patients; November 1982 through September 1986) and second half (56 patients; October 1986 through April 1989) of the experience. Other postoperative complications occurred in 16 patients (14%), 12 of whom experienced complications during the first half of the experience. At 22 +/- 20 (mean +/- SD) months' follow-up, 78 (76%) of 102 patients discharged were alive, and 24 patients (24%) had died. Fifty patients (49%) had experienced at least one automatic cardioverter-defibrillator discharge associated with hypotensive symptoms. The actuarial incidence of sudden death at 1, 2, and 3 years was 1.2%, 5.5%, and 6.2%, respectively. We concluded that the automatic implantable cardioverter-defibrillator is an effective therapy for refractory ventricular tachycardia/fibrillation and that device implantation at community hospitals with an experienced cardiac electrophysiology team is both feasible and practical.

Adult↗
PubMed2006

[Spanish registry of implantable cardioverter defibrillator. Second official report of the Spanish Society of Cardiology Working Group on Implantable Cardioverter Defibrillators (2005)].

INTRODUCTION AND OBJECTIVE: We report the results for the Spanish Registry on Implantable Cardioverter Defibrillators (ICD) (year 2005), developed by the Working Group on ICD of the Spanish Society of Cardiology. METHODS: Data were collected (prospectively in 77% of implants) by single page form questionnaires transmitted after the procedure to the Spanish Society of Cardiology. Participation was voluntary. RESULTS: The number of implants sent to the Registry was 2050 and this represents 74.4% of the total ICDs implanted. The implantation rate per million was 46.5 and the estimated total implantation rate per million was 62.5. The proportion of first implants was 70.3%. The majority of patients were males, with a median age of 65 years, severe or moderate to severe left ventricular dysfunction and in functional class II or I. Ischemic heart disease was the more frequent underlying heart disease followed by dilated cardiomyopathy. The main reason for ICD indication was secondary prevention related to sustained monomorphic ventricular tachycardia or aborted sudden cardiac death. A significant number of prophylactic indications were done, specially in non ischemic heart disease. The proportion of ICD implanted at the electrophysiology laboratory by cardiac electrophysiologist continues increasing. There was an increase in the number of ICD plus cardiac resynchronization therapy, that represent a 23.6% of the implants. The incidence of complications during the implant was very low. CONCLUSIONS: The National Registry on ICD, with a participation rate greater than in previous years, provides a representative sample of the ICD implants performed at our country.

Adolescent↗
PubMed2000

Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT.

The MADIT study lead to the first approved prophylactic indication for ICDs in patients with previous myocardial infarction, depressed left ventricular systolic function, nonsustained ventricular tachycardia (VT), and inducible sustained VT. However, criticisms have been raised with respect to the study design and patient selection. The MUSTT yielded similar results (51% lower mortality by ICD vs no antiarrhythmic drugs) in a comparable population. The results of MUSTT address the major criticisms of MADIT: (1) MADIT was a "small" study (n = 196), while MUSTT randomized 704 patients. (2) MADIT had an "imbalance" in its prescription of beta-blockers, whereas the "imbalance" favored the control group in MUSTT: (51% vs 34%). (3) MADIT had no untreated limb, but MUSTT did. (4) MADIT's control group mortality (32% at 2 years) was considered by some as "unrealistically high", yet MUSTT measured a similar rate (28% at 2 years). (5) MADIT presented no information relative to patients without inducible arrhythmias, but MUSTT recorded their outcomes in a registry. In conclusion, the combined results of MADIT and MUSTT confirm the appropriateness of their risk stratification schemes and the survival benefits of ICD therapy as a highly effective primary prevention in this high risk population.

Adrenergic beta-Antagonists↗
PubMed2006

[Eleven-years long follow-up in a patient after myocardial infarction, with low ejection fraction and recurrent ventricular tachycardia. The role of implantable cardioverter defibrillator and selective ablation].

The selective ablation of the recurrent ventricular tachycardia (VT) in a 75-year old patient after extensive inferior myocardial infarction (24 years ago), with low ejection fraction was performed. In 1995 the cardioverter-defibrillator was implanted due to recurrent, symptomatic VT. The coronary angiography in 1995 and in 2006 revealed the occlusion of the right coronary and the circumflex arteries. One year after implantation, he had electrical storm caused by proarrhythmic effect of amiodarone with prolongation of QT/QTc interval. During follow up episodes of VT (approximately 5/year) were successfully terminated by ATP and rarely by cardioversion. Recently, the patient was admitted to the hospital because of the very frequent (25/day) episodes of slow (500-560 ms), sustained ventricular tachycardia. The pharmacological treatment was unsuccessful. CARTO mapping and entrainment pacing revealed VT circuit around mitral annulus. A few applications at the paraseptal part of the mitral isthmus terminated VT, which was no longer inducible. During following days there were no VTs requiring ICD interventions.

Aged↗
PubMed1996

Ventricular arrhythmias and sudden cardiac death: an insight from recent multicenter randomized clinical trials.

While post-myocardial infarct patients with frequent ventricular premature contractions or nonsustained ventricular tachycardia (NSVT) are at an increased risk of sudden arrhythmic death, the empirical use of antiarrhythmic agents for such patients is no longer justified after the results of the Cardiac Arrhythmia Suppression Trial. A series of major breakthroughs in the design and clinical application of the implantable cardioverter defibrillator (ICD) have taken place over the past two decades since its invention by M Mirowski. Although there is a general consensus for the effectiveness of the ICD therapy in aborting sudden arrhythmic death, it is unknown whether the use of the ICD therapy results in prolonged survival. Three randomized clinical trials directed to the survivors of cardiac arrest due to ventricular tachycardia (VT) or ventricular fibrillation (VF) are currently in progress, comparing the ICD therapy with drug therapy (amiodarone, beta blockers, and sotalol). Already over seventeen hundred patients have been randomized and followed in these three clinical trials. All three trials continue currently indicating no emergence of statistically significant differences in total mortality between the two therapy groups. Prophylactic application of the ICD has been studied in the MADIT (Multicenter Automatic Defibrillator Implantation Trial)--the first randomized clinical trial dealing with implantable defibrillators. This study enrolled post-transmural infarct patients having documented NSVT, left ventricular dysfunction (ejection fraction 35% or lower) and inducible and nonsuppressible NSVT. The study was recently terminated because of an emergence of a highly significant lower mortality with the ICD therapy than with conventional drug therapy. The future for patients at an increased risk of sudden cardiac death is much brighter with future refinement of the ICD system and antiarrhythmic drug therapy, and with further improvement in the therapy directed at the underlying structural heart disease.

Arrhythmias, Cardiac↗
PubMed1999

Combined dynamic cardiomyoplasty and transvenous implantable cardioverter defibrillator system.

A transvenous implantable cardioverter defibrillator (ICD) was implanted in a patient with drug refractory ventricular fibrillation who had undergone latissimus dorsi cardiomyoplasty. The skeletal muscle was stimulated by a pulse train generator (cardiostimulator) implanted at the time of cardiomyoplasty. With proper programming of the devices neither adverse ICD-cardiostimulator interactions nor device malfunction were observed. Thus, the combined implantation of a cardiostimulator and an ICD is a feasible and safe therapeutic option.

Adult↗
PubMed1994

Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices.

INTRODUCTION: In acute canine studies, lidocaine, but not procainamide, increases defibrillation energy requirements. We evaluated the effects of lidocaine or procainamide on defibrillation energy requirements in 27 patients undergoing intraoperative testing for implantable cardioverter defibrillator device placement. METHODS AND RESULTS: Patients were tested off antiarrhythmic drugs and again following either lidocaine (200 to 250 mg loading and 3 mg/min maintenance infusions) or procainamide (1 gm loading and 3 to 4 mg/min maintenance infusions). The defibrillation testing protocol consisted of initial testing at 15 J, followed by higher or lower energies to determine the lowest energy producing three consecutive successful defibrillations. Overall, the mean defibrillation energy increased from 14 +/- 5 J to 18 +/- 7 J during lidocaine (plasma concentration 5.1 +/- 1.6 micrograms/mL; P < 0.02) but were similar at baseline (12 +/- 5 J) and during procainamide infusion (13 +/- 6 J) (plasma concentration: procainamide 10.7 +/- 7.2 micrograms/mL; N-acetyl procainamide 1.0 +/- 0.4 micrograms/mL). A positive linear correlation was found between lidocaine plasma concentration and percent change in defibrillation energy (lidocaine: r = 0.61; P = 0.01). Procainamide raised the defibrillation energy in three patients, two with supratherapeutic plasma concentrations. The increase in defibrillation energy equaled or exceeded 25 J in four patients after lidocaine and in one patient after procainamide. CONCLUSION: The data suggest that at high plasma concentrations, lidocaine and procainamide adversely affect defibrillation energy requirements consistent with an adverse, concentration-dependent effect of sodium channel blockade on defibrillation energy requirements in patients.

Aged↗
PubMed1996

New generations of implantable pacemaker defibrillators for ventricular and atrial tachyarrhythmias.

Implantable defibrillation devices have now been extensively applied to patients requiring cardioversion and defibrillation of sustained ventricular tachyarrhythmias. The focus of new developments is in improving technology, achieving physiologic operation in the atrium and ventricle, seeking new indications and identifying patient populations amenable to this therapy. Ventricular application technology is focusing on simplifying and improving robustness of lead systems yet seeking lower defibrillation thresholds. Dual chamber pacing, sensing and defibrillation are being developed. New populations for ventricular application include non-sustained ventricular tachycardia patients with coronary artery disease, dilated cardiomyopathy at risk for sudden death, long QT syndrome, pediatric patients with risk of sudden death and high risk postoperative coronary bypass patients. New applications include atrial defibrillation combined with atrial pacing in future devices. These devices are planned to have capabilities of ventricular defibrillation as a backup to address proarrhythmia concerns. It can be anticipated that implantable cardioverter defibrillator devices will be used for arrhythmia reversion in an expanding group of patients in the future.

Arrhythmias, Cardiac↗
PubMed1999

Erosion of the left ventricle by the epicardial patch of an automatic implantable cardioverter defibrillator.

A 56 year old man with an implantable cardioverter defibrillator was admitted with chest pain and collapse. Erosion of the left ventricle by an epicardial patch was confirmed by thoracotomy, but surgical repair was impossible. This rare complication should be considered in patients with a history of cardioverter defibrillators implanted by thoracotomy.

Defibrillators, Implantable↗
PubMed1994

Advances in implantable cardioverter-defibrillator therapy.

The use of implantable defibrillation systems in patients with cardiac arrest has resulted in lower mortality than expected from studies of similar patients not receiving defibrillators. Nonthoracotomy lead systems have led to a decrease in operative mortality and lowered the cost of defibrillator implantation, but these systems have a higher energy requirement for defibrillation than do epicardial ones. The recent introduction of single-lead systems and bipolar defibrillation pulses has simplified nonthoracotomy defibrillator implantation and improved defibrillation efficiency. A prototype unipolar, single-lead pectoral implant defibrillation system is described that may significantly improve the reliability, safety, and cost effectiveness of nonthoracotomy defibrillators. This and other improved nonthoracotomy systems may expand the indications for defibrillator implantation to prophylactic use in high-risk patients who have not yet experienced life-threatening ventricular arrhythmias.

Defibrillators, Implantable↗